

Special Issue

Cancer Immunotherapy and Vaccines Research

Message from the Guest Editors

Dear colleagues, Cancer vaccines are one of the main pillars of the cancer immunotherapy even in the era of checkpoint inhibitors. Indeed, although the latter have completely changed the scenario of cancer treatment, several patients do not benefit from them. However, the cancer vaccine field is still a work in progress field because an effective strategy has not been developed yet. The topic of the special issue will cover all the aspects involved in the vaccine research and development (i.e. identification of optimal target antigens, formulations, delivery strategies, adjuvants, combination with other immunomodulatory approaches).

Guest Editors

Dr. Luigi Buonaguro

Innovative Immunological Models Unit, National Cancer Institute - IRCCS "Pascale", Via Mariano, Semmola, 52, 80131 Napoli, Italy

Dr. Maria Tagliamonte

Laboratory of Innovative Immunological Models, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, 80131 Naples, Italy

Deadline for manuscript submissions

closed (28 February 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/63453

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).